Biointaxisis hosting a webinar titled “Get to Know Biointaxis and How to Invest in FRATAXAV® Gene Therapy to Cure Friedreich’s Ataxia” on 12 November at 5:00 pm.
Biointaxis, an academic spin-off from the Germans Trias i Pujol Research Institute (IGTP) founded in 2018, is developing the first drug designed to prevent and reverse the neurological and cardiac effects of Friedreich’s ataxia, based on ataxia research by an internationally recognised team led by Dr Antoni Matilla.
Friedreich’s ataxia is a rare, severe hereditary neurodegenerative disease with no effective treatment currently available. It is marked by progressive ataxia affecting gait, limbs and torso, speech disorders (dysarthria), cardiomyopathy, diabetes and loss of sensation and reflexes. Most patients become confined to a wheelchair by age 25.
The goal is to initiate Phase I clinical trials following FRATAXAV®’s outstanding preclinical results.
A crowdfunding campaign is now live on the Capital Cell platform: https://capitalcell.com/campaign/biointaxis-2024/. To date, over 60% of the required funds have already been secured.
Aimed at
Business angels, entrepreneurs, healthcare professionals, doctors, researchers, patients and families and anyone interested in supporting biomedical research and new innovative treatments for diseases with unmet medical needs.
Speakers
✔️ Antoni Matilla, CEO and co-founder of Biointaxis
✔️ Joan Mercadal, partner at Nara Capital
Programme
✔️ What is Biointaxis? Get to know our team, mission, the FRATAXAV® gene therapy drug and our future plans.
✔️Why is this project so important? Hear from lead scientist Dr Antoni Matilla on the transformative potential of FRATAXAV® and from principal investor Joan Mercadal, partner at Nara Capital, on why it presents an exciting investment opportunity.
✔️ FAQs: Get answers to your questions about the Capital Cell fundraising platform, how it works and how you can be part of this journey.
REGISTRATION (free): https://lu.ma/s1f8ienn
….
Further information
Biointaxis opens a €1 million crowdfunding round to launch the clinical phase of its gene therapy for Friedreich’s ataxia, partnering with the Centre for the Development of Technology and Innovation (CDTI) and Nara Capital
Biointaxis secures €2.17 million from the Ministry of Science and the European Commission to advance its gene therapy for Friedreich’s ataxia
Julia Otero interviews Dr Antoni Matilla, a leading scientist in ataxia and co-founder of Biointaxis, on her Onda Cero programme, discussing medical advances in the treatment of Friedreich’s ataxia
La mejor actitud que podemos adoptar es la de trat...
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
En nuestro post hablamos sobre este interesante tipo de célula del...
The results show that adenocarcinoma exhibits much more active and fun...
